sodium chlorite (HM-001) / HOIST - LARVOL DELTA

A Phase II Study of Intravesical HM-001 in Patients with Non–Muscle-Invasive Bladder Cancer Following Safe Completion of a Phase I Trial (AUA 2026) - No abstract available

Clinical • P1 data • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Development of a Novel Intravesical Therapy Using Sodium Chlorite (HM-001) for Bladder Cancer: Transition from Preclinical to Clinical trial (EMUC 2024) - "Furthermore, the fact that it is effective against high-grade and low-grade PDX-derived bladder cancer tissues indicates that it may be widely applicable to patients with NMIBC. A Phase I/IIa, multi-center, open-label, investigator-initiated study of HM-001 is currently underway in patients with non-muscle invasive bladder cancer undergoing TURBT."

Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Development of HM-001 as a therapeutic drug for non-muscle invasive bladder cancer (AACR 2024) - "HM-001 is a drug containing sodium chlorite as the active ingredient that is being developed as a drug for non-muscle invasive bladder cancer (NMIBC), and is currently undergoing physician-led clinical trials...In particular, low-grade forms are restricted to low- and intermediate-risk groups. The results of this study show that HM-001 is effective not only for high-risk (including CIS) NMIBC but also for low- and intermediate-risk (low-grade) NMIBC."

Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor